List view / Grid view
6 August 2015 | By Synthesis and Solid State Pharmaceutical Centre (SSPC)
Read how the Synthesis and Solid State Pharmaceutical Centre (SSPC) is positioning Ireland as a global hub for advanced pharmaceutical manufacturing...
6 July 2015 | By Caroline Richards, Editor
Inspired by her attendance at ISSCR 2015, Editor of Drug Target Review, Caroline Richards, discusses stem cells and the rise of unregulated stem cell practitioners...
Cancer cells are addicted to glucose and glutamine, which enables them to generate the energy and macromolecule synthesis intermediates to support their growth...
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…
Procedures for cardiac differentiation of human pluripotent stem cells (hPSCs) have greatly improved over the past few years. The facilitated derivation of hPSC-cardiomyocytes has enabled the thorough assessment of their physiology and manipulation of their properties. Moreover, patient-specific hPSCs generated through cellular reprogramming allow for cardiac disease modelling, discovery of…
10 June 2015 | By Drug Target Review
Included in this issue: Drug Discovery, Screening, Hit-to-Lead, Antibodies, Stem Cells, Kinases and much more...
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
This Stem Cells In-Depth Focus features articles on stem cell-derived cardiomyocytes, and their use in drug discovery and development, as well as a look at how venom could be used in stem cell differentiation...
10 June 2015 | By Kenji Schorpp, Kamyar Hadian, Sheraz Gul, Horst Flotow
In this Screening In-Depth Focus, high throughput screening is the topic focused on by Kenji Schorpp and Kamyar Hadian, Institute of Molecular Toxicology and Pharmacology, and Sheraz Gul, Fraunhofer Institute for Molecular Biology and Applied Ecology. They discuss the importance of the technique in drug discovery today as well as…
10 June 2015 | By Molecular Devices
Molecular Devices discusses stem cells research and the company’s latest technological advancements in this exciting field...
Dementia is a global crisis with 76 million people worldwide expected to be living with the condition by 2030. Current symptomatic treatments provide modest improvements in cognition but disease-modifying therapies for diseases like Alzheimer’s – the most common cause of dementia – do not yet exist.
10 June 2015 | By IntelliCyt Corporation
The immune system plays a vital role in keeping us alive but also participates in many diseases adversely affecting quality of life across the globe. It can be over activated, leading to a variety of inflammation and autoimmune diseases, or suppressed, leading to a vast array of diseases from AIDS…
Academia and pharma have always been uneasy bedfellows. There has in the past been tension between both caused by a range of issues that neither party was willing to try and resolve. However, there is a new impetus to solve these issues as both parties have started to realise that…
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…
